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Abstract
Background: Renal tubulointerstitial fibrosis (TIF) plays an important role in the progression of chronic kidney disease
(CKD) and its pathogenesis involves epithelial-to-mesenchymal transition (EMT) upon renal injury. Recombinant human
erythropoietin (rhEPO) has been shown to display novel cytoprotective effects, in part by inhibiting transforming
growth factor (TGF)-β1-induced EMT. Here, we evaluated the inhibitory effects of microparticles (MPs) derived from
human EPO gene-transfected kidney mesenchymal stem cells (hEPO-KMSCs) against TGF-β1-induced EMT in Madin-
Darby canine kidney (MDCK) cells and against TIF in mouse kidneys with unilateral ureteral obstruction (UUO).
Methods: EMT was induced in MDCK cells by treatment with TGF-β1 (5 ng/mL) for 48 h and then inhibited by co-
treatment with rhEPO (100 IU/mL), mock gene-transfected KMSC-derived MPs (MOCK-MPs), or hEPO-KMSC-derived MPs
(hEPO-MPs) for a further 48 h. UUO was induced in FVB/N mice, which were then treated with rhEPO (1000 IU/kg,
intraperitoneally, every other day for 1 week), MOCK-MPs, or hEPO-MPs (80 μg, intravenously). Alpha-smooth muscle
actin (α-SMA), fibronectin, and E-cadherin expression were evaluated in MDCK cells and kidney tissues, and the extent
of TIF in UUO kidneys was assessed by immunohistochemical staining.
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Results: TGF-β1 treatment significantly increased α-SMA and fibronectin expression in MDCK cells and decreased that of
E-cadherin, while co-treatment with rhEPO, MOCK-MPs, or hEPO-MPs markedly attenuated these changes. In addition,
rhEPO and hEPO-MP treatment effectively decreased phosphorylated Smad2 and Smad3, as well as phosphorylated p38
mitogen-activated protein kinase (MAPK) expression, suggesting that rhEPO and rhEPO-MPs can inhibit TGF-β1-induced
EMT via both Smad and non-Smad pathways. rhEPO and hEPO-MP treatment also significantly attenuated the extent of
renal TIF after 1 week of UUO compared to MOCK-MPs, with hEPO-MPs significantly reducing myofibroblast and F4/80+
macrophage infiltration as well as EMT marker expression in UUO renal tissues in a similar manner to rhEPO.
Conclusions: Our results demonstrate that hEPO-MPs modulate TGF-β1-induced EMT in MDCK cells via the Smad2,
Smad3, and p38 MAPK pathways and significantly attenuated renal TIF in UUO kidneys.
Keywords: Microparticles, Transforming growth factor-β1, Renal fibrosis, Epithelial-to-mesenchymal transition,
Erythropoietin
Background
Renal tubulointerstitial fibrosis (TIF) is characterized by
a complex process involving inflammatory cell infiltra-
tion, loss of renal tubule epithelial cells (TECs),
epithelial-to-mesenchymal transition (EMT), myofibro-
blast accumulation, and excessive extracellular matrix
(ECM) deposition [1]. Renal tubular EMT is thought to
be an important mechanism that leads to TIF, with re-
cent studies finding that some interstitial alpha-smooth
muscle actin (α-SMA)-positive myofibroblast popula-
tions are derived from TECs via EMT [2, 3]. Transform-
ing growth factor beta (TGF-β) is a pivotal mediator of
renal TIF pathogenesis [4, 5], and detailed studies in
both experimental animal and human disease models
have demonstrated that TGF-β1 and its receptors are
highly upregulated and stimulate EMT in renal TIF [6].
Indeed, experimental TGF-β inhibition has been shown
to significantly reduce the expression of EMT markers
and ameliorate TIF [7, 8]. For instance, hepatocyte
growth factor and bone morphogenic protein-7 inhibit
α-SMA overexpression and E-cadherin underexpression
triggered by TGF-β1, thus preventing renal interstitial fi-
brosis in obstructed kidneys [9, 10]. As such, interven-
tions that block or inhibit EMT could be potential
therapeutic strategies for treating chronic progressive
renal fibrosis.
Erythropoietin (EPO) is a 30.4-kDa glycoprotein hor-
mone produced primarily by the kidneys that regulates
red blood cell production in response to anemia [11]. In
addition to its hematopoietic effects, recent studies have
highlighted the cytoprotective effects of EPO in kidney
tissues [12], while EPO has been shown to ameliorate
cisplatin-induced and ischemia-reperfusion renal injuries
without affecting hemoglobin [13] and inhibit the apop-
tosis of TGF-β1-treated LLC-PK1 cells in vitro [4, 14].
EPO treatment has also been found to reduce renal
fibrosis in a murine model of unilateral ureteral obstruc-
tion (UUO) by inhibiting TGF-β1-induced EMT [15],
suggesting that inhibition of EMT by EPO
administration could be a potential therapeutic strategy
to inhibit or slow CKD progression. Indeed, chronic ad-
ministration of low-dose long-acting EPO was found to
ameliorate tubulointerstitial damage and preserve renal
function in 5/6 remnant kidney models [16]. However,
prolonged infusion of low-dose EPO is technically diffi-
cult and impractical in a clinical environment. In
addition, clinical application of soluble growth factor
proteins such as EPO is limited by their short-half life,
rapid enzymatic inactivation, and inefficient delivery to
target tissues [17]. Moreover, the direct injection of high
doses of growth factors to achieve an effective local con-
centration in target tissues may cause unexpected side
effects in vivo. To overcome this challenge, recent stud-
ies have used genetically modified mesenchymal stem
cells (MSCs) that secrete EPO (MSC-EPO) to deliver
EPO to target tissues [18, 19]; however, their poor long-
term cellular viability and potential induction of anti-
EPO antibodies have limited their widespread use [20].
Microparticles (MPs) are submicron-sized vesicles re-
leased by a variety of cells, including stem cells, in re-
sponse to oxidative stress or hypoxia. Stem cell-derived
MPs can mimic the biological activities of the original
stem cells and interact with target cells via specific
receptor-ligand interactions to mediate the transfer of
proteins, bioactive lipids, mRNA, and miRNAs [21] to
neighboring diseased or injured cells, thereby promoting
the activation of regenerative programs [22, 23]. Previ-
ously, we demonstrated that the administration of kid-
ney MSC-derived MPs (KMSC-MPs) repairs injured
tissue and improves renal function via an mRNA-
dependent mechanism in an experimental murine model
of acute kidney injury. KMSC-MPs carried proangio-
genic signals and ameliorated peritubular capillary rar-
efaction by inhibiting EMT in UUO kidneys, thus
presenting an effective tool for stem cell-based therapy
[24]. MPs have a superior safety profile to stem cell-
based therapies as they have lower propensity to trigger
immune responses and are unable to differentiate into
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tumor cells [22, 23]. In addition, MPs can be safely
stored for extensive periods of time without losing their
function [25]. However, our preliminary experiments
using KMSC-derived MPs failed to demonstrate greater
TGF-β-induced EMT inhibition in vitro or renal fibrosis
improvements in UUO kidneys compared to direct
rhEPO administration. Since MP characteristics depend
on the cell of origin and the external stimuli or injury,
recent studies have used preconditioning or gene modifi-
cation to enhance the therapeutic efficacy of MSC-
derived MPs [26]. In particular, MPs derived from
hypoxia-preconditioned MSCs promoted angiogenesis
more than those derived from MSCs cultured under
normoxic conditions [27, 28], while gene overexpression
enhanced the therapeutic efficacy of MSC-derived MPs
in various disease models [29, 30].
Therefore, using MPs derived from EPO mRNA-
overexpressing MSCs could be an appealing therapeutic
strategy to effectively deliver EPO mRNA to target cells
and promote tissue repair or regeneration. Here, we hy-
pothesized that EPO mRNA-enriched MPs (hEPO-MPs)
could be isolated from human EPO gene-transfected
KMSCs (hEPO-KMSCs) and exert greater renoprotective
effects than rhEPO. Consequently, we investigated
whether hEPO-MP treatment could inhibit EMT in
TGF-β1-treated Madin-Darby canine kidney (MDCK)
cells in vitro and whether these inhibitory effects were
mediated by changes in the Smad and p38 mitogen-
activated protein kinase (MAPK) pathways. Moreover,
we investigated whether hEPO-MPs had greater anti-
fibrotic effects than MOCK-MPs in a murine model of
UUO.
Methods
Human EPO mRNA-transfected KMSC generation and MP
isolation
KMSCs isolated from an FVB male mouse kidney were
cultured on gelatin-coated dishes in α-minimum essen-
tial medium (MEM) with 10% horse serum (Gem Bio-
tech, Woodland, CA, USA) to 80% confluence, as
previously described [31]. These KMSCs were trans-
fected with the human EPO gene and used to generate
MPs. Briefly, HEK293T cells (SeouLin Bioscience,
Seongnam, South Korea), used as packaging cells, were
transfected with a lentiviral expression vector containing
EPO, copGFP, and packaging construct to generate lenti-
viral supernatants [32]. Meanwhile, empty control vec-
tors were used to generate MOCK-KMSCs. After the
KMSC cells had been transduced, hEPO-KMSCs were
identified by cop green fluorescent protein (GFP) expres-
sion using fluorescence microscopy and EPO mRNA re-
verse transcription polymerase chain reaction (RT-PCR).
The hEPO-KMSCs were then cultured on gelatin-coated
dishes in MEM with 10% horse serum (Gem Biotech,
Woodland, CA, USA), as described previously [31]. EPO
secretion was measured in the supernatant of the hEPO-
KMSCs by an enzyme-linked immunosorbent assay
(ELISA) specific for human EPO (Quantikine, R&D Sys-
tems, Minneapolis, IL, USA).
To isolate hEPO-MPs, hEPO-KMSCs were cultured in
serum-free α-MEM (Gibco, Carlsbad, CA, USA) and 1%
O2 in a controlled atmosphere chamber using an O2
analyzer (Thermo Scientific, Marietta, OH, USA) for 24
h. Cell debris was removed by centrifugation at 2000×g
for 10 min at room temperature and the cell-free super-
natants were centrifuged at 50,000×g (Beckman Coulter
Optima L-90 K Ultracentrifuge, CA, USA) for 2 h at 4 °C
before being washed in phosphate-buffered saline (PBS)
and centrifuged again under the same conditions.
MOCK-MPs were isolated from the MOCK-KMSCs
using the same protocol. hEPO-MP and MOCK-MP pel-
lets were suspended in culture medium for the MDCK
cell experiments and labeled with CellTracker™ (Invitro-
gen, Carlsbad, CA, USA) to allow them to be traced dur-
ing in vivo and in vitro functional experiments.
Characterization of isolated MPs
To analyze the characteristics of the isolated MPs, MP-
containing pellets were resuspended in sterile 1× PBS or
1× Annexin V Binding Buffer (BD Biosciences, San
Diego, CA, USA) consisting of 0.1M HEPES/NaOH
(pH 7.4), 1.4M NaCl, and 25 mM CaCl2, and diluted 1:
10 with distilled water for 1 h at 4 °C. Samples were kept
on ice in the dark until flow cytometric analysis was per-
formed using the following PE-conjugated antibodies:
CD29, CD44, and CD73 (Biolegend, San Diego, CA,
USA), as described previously with the BD FACS Canto
II (BD Biosciences, San Jose, CA, USA). PE-conjugated
isotype-matched antibodies were used as a negative con-
trol. Different sized beads (0.1, 0.2, 0.5, 1 μm, Invitrogen,
Carlsbad, CA, USA) were used as size markers while a
log scale was used to analyze forward (FSC) scatter and
side (SSC) light scatter parameters. Spectral overlap
compensation between fluorochrome channels was car-
ried out for each experiment using single-color-stained
MP populations. For each experimental sample, a corre-
sponding isotype control or positive/negative MP popu-
lations were used to set gates. All data were analyzed
using FlowJo software (TreeStar Inc., Ashland, OR,
USA). Size distribution of the MPs was determined using
nanoparticle tracking analysis (NanoSight NS300, Mal-
vern Instruments, Malvern, UK).
MDCK cell culture and treatment with rhEPO or MPs
To assess the effects of rhEPO and MPs in vitro, we used
MDCK cells purchased from the Korean Cell Line Bank
(Seoul, South Korea). The cells were seeded into six-well
culture plates (5 × 104 cells/well) with complete
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Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS; Gibco, Carls-
bad, CA, USA), penicillin G (100 U/mL), and
streptomycin (100 U/mL) and cultured at 37 °C in 5%
CO2 for 48 h. The cells were incubated in serum-free
medium for 24 h and transferred into DMEM with 1%
FBS (vehicle) or stimulated with recombinant human
TGF-β1 (5 ng/mL, PeproTech, Rocky Hill, NJ, USA cat
no. 100-21) for 48 h. The medium was changed and the
cells were treated with TGF-β1 (5 ng/mL), MOCK-MPs
(4 μg/mL), hEPO-MPs (4 μg/mL), or rhEPO (100 IU/mL)
for a further 48 h. Incorporation of red fluorescent Cell-
Tracker™-labeled MPs into the cell cytoplasm was de-
tected using a fluorescence microscope, and changes in
MDCK cell morphology were assessed.
Immunocytochemical staining of EMT markers
Treated MDCK cells were washed twice with PBS (pH
7.4), immediately fixed with 4% formaldehyde diluted in
PBS for 15 min at room temperature, and permeabilized
with 0.2% Triton X-100 for 10 min. The cells were then
blocked with 1% bovine serum albumin for 30 min at
room temperature, incubated overnight at 4 °C with the
corresponding antibodies, and rhodamine-conjugated
antibodies against rabbit IgG were used to detect the
primary antibodies. Samples were stained with 4,6-dia-
midino-2-phenylindole (DAPI) and mounted using a
Slow Fade Light Antifade kit with DAPI (Molecular
Probes, Eugene, Oregon, USA). Immunostained cells
were visualized using an LSM-780 META confocal
microscope (Carl Zeiss, Oberkochen, Germany) at a
wavelength of 405 nm for DAPI, 488 nm for GFP, and
647 nm for rhodamine. Fluorescence intensity was
assessed by examining at least five fields per section
under × 400 magnification by MetaMorph digital image
analysis (BioVision, Exton, PA, USA).
Immunoblotting of EMT markers and Smad/non-Smad
proteins in MDCK cells
For western blotting, MDCK cells were lysed in 300 μL
of cell lysis buffer containing 150 mM NaCl, 1% IGEP
AL® CA-630, 0.5% sodium deoxycholate, 0.1% sodium
dodecyl sulfate (SDS), 50 mM Tris (pH 8.0), and a prote-
ase inhibitor cocktail (Thermo Fisher Scientific, Wal-
tham, MA, USA). Whole cell lysates were resolved by
sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) gel
electrophoresis and transferred onto polyvinylidene
fluoride membranes (Millipore, Billerica, MA, USA).
After blocking with 5% skim milk, the membranes were
incubated with primary antibodies against E-cadherin (1:
500; BD Biosciences, Bedford, UK), α-SMA (1:10000;
R&D, Minneapolis, IL, USA), fibronectin (1:1000; Santa
Cruz, CA, USA), phospho-p38 (1:1000; Santa Cruz), p38
(1:1000; Abcam, Cambridge, UK), phospho-Smad2 (1:
500; Millipore), Smad2 (1:1000; Santa Cruz), phospho-
Smad3 (1:500; Abcam), Smad3 (1:1000; Cell Signaling
Technology, Danvers, MA, USA), and GAPDH (1:1000;
Cell Signaling Technology, Danvers, MA, USA). The
membranes were then washed three times in 1× PBS
with Tween-20 (VWR Amresco, Solon, Ohio, USA) for
5 min and incubated with horseradish peroxidase-
conjugated secondary antibodies. Target proteins were
visualized using Amersham ECL Western Blotting De-
tection Reagent (GE Healthcare Life Sciences). Band
densities were measured using NIH Image J software.
Quantitative real-time polymerase chain reaction (qRT-
PCR) of MDCK cells
Total RNA was isolated from MDCK cells using an
RNeasy Mini Kit (QIAGEN, Germantown, MD, USA)
and cDNA was synthesized using a DNA Synthesis Kit
(QIAGEN). qRT-PCR was performed using an ABI Ste-
pOnePlus real-time PCR system (Applied Biosystems,
Beverly, MA, USA) with double-stranded DNA synthesis
monitored using SYBR Green (Applied Biosystems).
Triplicate test reactions were carried out for each sample
to analyze gene expression, which was normalized to β-
actin mRNA expression. Negative cDNA controls were
cycled in parallel with each run. The primer sequences
are listed in Table 1.
Animal experiments
Adult FVB/N mice (five to seven weeks old) were pur-
chased from Koatech (Gyeonggi-Do, Korea). The ani-
mals were maintained under temperature-controlled
conditions with a 12-h light/dark cycle and were pro-
vided with water and food ad libitum. UUO was per-
formed using an established protocol [24]. Briefly, FVB
mice were anesthetized with isoflurane plus oxygen and
placed on a heating pad (Jeung Do Bio & Plant Co,
Seoul, Korea) to maintain their temperature at 37 °C.
The left ureter was exposed using a flank incision and li-
gated with 3–0 silk at two points just below the lower
pole of the left kidney, and then, the peritoneal mem-
brane and skin were sutured. Sham animals underwent
the same procedure, except that the ureter was not li-
gated. Following surgery, the mice were randomly di-
vided into four groups and administered the vehicle
(150 μL saline) only, MOCK-MPs (80 μg/150 μL), or
hEPO-MPs (80 μg/150 μL) via the tail vein (n = 5 per
group). In the rhEPO-treated group, rhEPO (1000 U/kg)
was administered intraperitoneally every other day. Our
previous study showed that 7 days of UUO could induce
significant TIF in FVB/N mice [24]. Therefore, all mice
were sacrificed 7 days after UUO surgery, and the unilat-
erally obstructed kidney was harvested for tissue collec-
tion. Half of the kidney tissue was fixed in 4%
paraformaldehyde (PFA) for subsequent histology and
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immunofluorescence, while the remaining half was flash
frozen for protein and mRNA isolation.
Immunohistochemical and immunofluorescence analysis
To analyze kidney fibrosis, kidney sections were stained
with Sirius red, Masson’s trichrome, and anti-α-SMA
(Sigma) and examined by light microscopy. Positive Sir-
ius red, Masson’s trichrome, and anti-α-SMA (Sigma)
staining areas were evaluated relative to the unit area
and expressed as a percentage per unit area using Meta-
Morph microscopy image analysis software (Molecular
Devices, Sunnyvale, CA, USA). Macrophage immunohis-
tochemistry was performed using anti-F4/80 (Abcam)
antibodies and F4/80-positive cells quantified as the
number of cells per high power field [24]. Microscopy
assessment was carried out in a blinded manner, with 20
randomly selected fields from each slide section exam-
ined at × 400 magnification. To trace MPs in vivo,
freshly isolated MPs were labeled with red fluorescent
CellTracker™ and detected within the peritubular inter-
stitium of kidney sections by immunofluorescence
microscopy.
Immunoblotting of renal fibrosis markers
For western blotting, mouse kidney tissues were lysed in
300 μL of cell lysis buffer containing 150 mM NaCl, 1%
IGEPAL® CA-630, 0.5% sodium deoxycholate, 0.1% so-
dium dodecyl sulfate (SDS), 50 mM Tris (pH 8.0), and a
protease inhibitor cocktail (Thermo Fisher Scientific).
Kidney tissue lysates were resolved by sodium dodecyl
sulfate-polyacrylamide (SDS-PAGE) gel electrophoresis
and transferred onto polyvinylidene fluoride membranes
(Millipore), blocked with 5% skim milk, and incubated
with primary antibodies against E-cadherin (1:1000;
Santa Cruz), collagen I (1:500; Santa Cruz), α-SMA (1:
10000; R&D), fibronectin (1:1000; Santa Cruz), TGF-β1
(1:1000; Santa Cruz), and GAPDH (1:1000; Cell Signal-
ing Technology). The membranes were then washed
three times with 1× PBS with Tween-20 (AMRESCO®)
for 5 min, incubated with horseradish peroxidase-
conjugated secondary antibodies, and washed again
using the same procedure. Target proteins were visual-
ized using Amersham ECL Western Blotting Detection
Reagent (GE Healthcare Life Sciences), and band density
was measured using NIH Image J software.
Statistical analysis
Data were expressed as the mean ± standard deviation
and were statistically analyzed using SPSS 18.0 software
(SPSS Inc., Chicago, IL, USA). Between-group compari-
sons were made by one-way analysis of variance
(ANOVA) followed by the Student-Newman-Keuls test.
Multiple tests were applied only when a significant dif-
ference was determined by ANOVA. P values of < 0.05
were considered statistically significant. All experiments
were repeated at least three times with similar results.
Results
hEPO-KMSC generation and hEPO-MP characterization
Cultured hEPO-KMSCs were identified following lenti-
viral transduction by copGFP expression using fluores-
cence microscopy (Fig. 1a), with flow cytometric analysis
revealing a transfection efficiency of > 99% based on the
percentage of copGFP-expressing cells (Fig. 1b). In
addition, hEPO mRNA expression was confirmed by
RT-PCR with cDNA isolated from hEPO-KMSCs and
hEPO-MPs (Fig. 1c, right and left panels, respectively).
In vitro EPO secretion was measured in 24 h condi-
tioned supernatant, revealing that MOCK-KMSCs did
not secrete detectable levels of EPO, whereas hEPO-
KMSCs produced ~ 75 IU of EPO per 1 × 106 cells (Fig.
1d). On average, the MPs were 225.5 nm in size, while
both hEPO-MPs and MOCK-MPs were positive for
Annexin V (> 90%) and expressed CD29, CD44, and
CD73, similarly to their cells of origin (Fig. 1e and Sup-
plementary Fig. 1).
hEPO-MP treatment suppressed TGF-β1-induced EMT in
MDCK cells
To evaluate whether hEPO-MP treatment could affect
TGF-β1-induced EMT, we examined the effect of hEPO-
MPs on the expression of EMT markers in MDCK cells.
MDCK cells were cultured with 5 ng/mL of TGF-β1 for
48 h to induce EMT, as confirmed by a change in the
morphology of TGF-β1-treated cells from cuboidal to an
elongated spindle shape (Fig. 2A a, b, p, q). Following
treatment with CellTracker™-labeled hEPO-MPs, their
incorporation into the cytoplasm of MDCK cells was ob-
served (Fig. 2A n, s) alongside the direct transfer of EPO
mRNA into target MDCK cells, as demonstrated by RT-
PCR (Fig. 2B). Moreover, co-treatment of TGF-β1-
treated MDCK cells with MOCK-MPs, hEPO-MPs, or
Table 1 qRT-PCR primers
Gene Forward primers (5′ to 3′) Reverse primers (5′ to 3′)
Canine E-cadherin CTGTCACTGTGGACGTGGAA CTTGCGCCGTGTGTTAGTTCC
Canine vimentin AACCGGAACAATGATGCCCT CATTTCACGCATCTGGCGTT
Canine α-SMA ATGCAGAAGGAGATCACCGC CACAGAGCAAGGAAGCGTCT
β-actin CGCAATGAAGTGGAGTCTGA ATAGCAGCAGACAGAGGCAAC
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Fig. 1 (See legend on next page.)
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rhEPO reversed TGF-β1-induced morphological changes
(Fig. 2A c–e).
Changes in E-cadherin and vimentin expression are
the most important features of EMT. In this study, we
examined the expression of EMT-related factors E-
cadherin, fibronectin, vimentin, and α-SMA accompany-
ing changes in MDCK cell morphology, using immuno-
fluorescence staining (Fig. 2C). E-cadherin expression
was significantly lower in TGF-β1-treated MDCK cells
than in the control MDCK cells, whereas vimentin, α-
SMA, and fibronectin expression levels were higher.
Treatment with MOCK-MPs, hEPO-MPs, or rhEPO in-
creased E-cadherin expression on the cell membrane
and decreased vimentin, α-SMA, and fibronectin expres-
sion in the cytoplasm. Consistent with the observed
changes in cell morphology, TGF-β1 treatment signifi-
cantly downregulated E-cadherin and upregulated α-
SMA and vimentin mRNA expression (Fig. 3A–C), while
co-treatment with MOCK-MPs, hEPO-MPs, or rhEPO
ameliorated these changes. Notably, E-cadherin expres-
sion was significantly higher in the hEPO-MP or rhEPO-
treated groups than in those treated with MOCK-MPs;
however, MOCK-MPs, hEPO-MPs, and rhEPO all sig-
nificantly and comparably reduced α-SMA and vimentin
mRNA expression.
Immunoblot analysis also demonstrated that TGF-β1
significantly decreased E-cadherin and increased α-SMA
and fibronectin protein levels in MDCK cells. Moreover,
these changes were effectively reversed by treatment
with MOCK-MPs, hEPO-MPs, or rhEPO (Fig. 3D–G).
In particular, hEPO-MPs decreased α-SMA and fibro-
nectin expression more effectively than MOCK-MPs or
rhEPO, whereas hEPO-MPs and rhEPO significantly in-
creased E-cadherin expression compared to MOCK-
MPs.
hEPO-MPs attenuate TGF-β1-induced upregulation of
Smad2, Smad3, and p38 MAPK phosphorylation in MDCK
cells
Previous studies have demonstrated that rhEPO attenu-
ates the upregulation of Smad2 phosphorylation and in-
hibits EMT in TGF-β1-treated MDCK cells. Here, we
investigated whether hEPO-MP treatment also modulates
TGF-β1-induced EMT by inhibiting the Smad signaling
pathway. Phosphorylated Smad2 and Smad3 (p-Smad2
and p-Smad3, respectively) protein levels were analyzed in
MDCK cells by immunoblotting (Fig. 4A–D), revealing
that both p-Smad2 and p-Smad3 expression, as well as the
p-Smad2 to Smad2 and p-Smad3 to Smad3 ratios were
significantly higher in TGF-β1-treated MDCK cells than
in the control MDCK cells. Consistent with our previous
findings, a single dose of hEPO-MPs significantly reduced
p-Smad2 expression and the p-Smad2 toSmad2 ratio in a
manner comparable to rhEPO. Conversely, MOCK-MPs
failed to significantly decrease p-Smad2 expression or the
p-Smad2 toSmad2 ratio but reduced p-Smad3 expression
and the p-Smad3 to Smad3 ratio. Of note, MOCK-MPs
reversed TGF-β1-mediated changes in EMT markers in
MDCK cells. TGF-β1-mediated EMT is known to be reg-
ulated by pathways other than Smad signaling, including
the p38 MAPK signaling pathway, which is induced by
TGF-β1 [33]. Therefore, we investigated whether rhEPO
or MP treatment affected p38 MAPK signaling in TGF-
β1-induced EMT by measuring phosphorylated p38 (p-
p38) MAPK and p38 MAPK expression in TGF-β1-
treated MDCK cells (Fig. 4E, F). Stimulation with TGF-β1
markedly increased p-p38 MAPK expression compared to
the control, while MOCK-MP, rhEPO-MP, and rhEPO
treatment significantly suppressed p-p38 MAPK expres-
sion in TGF-β1-mediated EMT.
hEPO-MP treatment ameliorated renal fibrosis in UUO
kidneys
To assess the beneficial effects of hEPO-MPs on renal fi-
brosis, we used an UUO mouse model. First, we exam-
ined whether CellTracker™-labeled MPs were delivered
into the kidneys after their injection via the tail vein, and
found labeled MPs selectively in the interstitial areas of
the UUO kidneys in vivo (Supplement Fig. 2). Next, we
investigated the degree of renal TIF in UUO kidneys
with Sirius red and Masson’s trichrome staining; vehicle-
treated UUO kidneys showed significantly higher
collagen expression than the sham-operated kidneys.
Although both MPs and rhEPO significantly reduced
collagen deposition in the UUO kidneys, the kidneys
treated with hEPO-MP and rhEPO showed a greater de-
crease in TIF than the MOCK-MP-treated kidneys
(Fig. 5A a–j, B, C).
(See figure on previous page.)
Fig. 1 hEPO-KMSC generation and hEPO-KMSC and hEPO-MP characterization. a Fluorescence microscopy revealed that hEPO-KMSCs expressed
copGFP and b flow cytometry demonstrated efficient transfection. c RT-PCR detection of hEPO mRNA in hEPO-KMSCs and hEPO-MPs. d hEPO
secretion by hEPO-KMSCs measured by ELISA on unconditioned culture media or 24 h conditioned media from MOCK- or hEPO-KMSCs. e Flow
cytometry analysis of cell surface marker (CD29, CD44, CD73) and Annexin V expression on hEPO-MPs (upper panel) and MOCK-MPs (lower
panel). Red lines indicate CD29, CD44, CD73, and Annexin V expression. Black lines indicate isotypic controls. Data are representative of three
independent experiments. Magnification, × 400. Scale bar, 100 μm (white)
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Fig. 2 (See legend on next page.)
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hEPO-MP treatment decreased UUO-induced renal
myofibroblast accumulation in renal tissue
Myofibroblasts are an activated fibroblast phenotype that
are responsible for extracellular matrix deposition during
TIF and are recognized as an important factor in disease
progression. Immunohistochemical staining for the myo-
fibroblast marker α-SMA and quantitative analysis of α-
SMA-positive areas revealed that the α-SMA-positive
area was almost 6-fold higher in the UUO experimental
group than in the sham-operated control group. How-
ever, treatment with rhEPO or both MPs significantly
decreased the α-SMA-positive area in UUO kidneys,
particularly those treated with rhEPO (Fig. 5A k–o, D),
while hEPO-MPs and MOCK-MPs yielded comparable
reductions.
hEPO-MP treatment reversed EMT markers and renal
fibrosis in UUO kidneys
Next, we investigated changes in EMT (α-SMA and E-
cadherin) and renal fibrosis (collagen I and TGF-β1)
markers in UUO kidneys. Western blot analysis of
vehicle-treated UUO kidneys revealed significant in-
creases in α-SMA, collagen I, and TGF-β1 expression
compared to that in sham-operated control kidneys
(Fig. 6). MOCK-MPs, hEPO-MPs, and rhEPO reversed
these changes, consistent with the results of the in vitro
experiments using MDCK cells. In particular, rhEPO
treatment most effectively reduced α-SMA and collagen
I levels in UUO kidneys. Conversely, E-cadherin expres-
sion was significantly decreased in UUO kidneys but in-
creased with rhEPO, MOCK-MP, and hEPO-MP
treatment. Taken together, these findings indicate the
renoprotective effects of MPs in vivo.
hEPO-MP treatment ameliorates UUO-induced renal
inflammatory cell infiltration
To further investigate the anti-fibrotic effects of hEPO-
MPs, we assessed F4/80-positive macrophage infiltration
into the tubulointerstitial area of UUO kidneys. Semi-
quantitative MetaMorph analysis revealed that infiltra-
tion of F4/80-positive macrophages increased signifi-
cantly in vehicle-treated UUO kidneys but decreased
significantly when the kidneys were treated with hEPO-
MPs, MOCK-MPs, and rhEPO (71.5 ± 0.08%, 44.8 ±
0.03%, and 36.5 ± 0.05% of vehicle control; Fig. 5A p–t,
E). In particular, hEPO-MPs and rhEPO reduced F4/80-
positive cell infiltration by 2-fold more than MOCK-
MPs, suggesting that hEPO-MPs have a significantly
greater capacity to inhibit F4/80-positive macrophage in-
filtration than rhEPO.
Discussion
Recent studies have suggested that EMT of renal tubular
epithelial cells is a major contributor to myofibroblasts
and fibroblasts during renal fibrogenesis [34, 35]; thus,
inhibiting or improving EMT could be a valuable thera-
peutic strategy for inhibiting renal fibrosis. Moreover,
studies have demonstrated that EPO has cytoprotective
effects, while rhEPO treatment inhibits EMT in renal
TECs. In this study, we investigated whether hEPO-MPs
could improve MSC-based renal fibrosis treatment. Our
findings revealed that hEPO-MPs were associated with
the direct transfer of EPO mRNA to target cells and
inhibited TGF-β1-induced EMT in MDCK cells by regu-
lating p-Smad and p-p38 MAPK signaling. Moreover,
hEPO-MPs reduced TGF-β1 and EMT marker expres-
sion and inhibited inflammatory macrophage infiltration
in UUO kidneys, suggesting that hEPO-MP treatment
may inhibit renal fibrosis.
Preclinical studies have shown that stem cell-based
therapies could be a promising novel therapeutic strat-
egy to slow the progression of renal diseases; in particu-
lar, MSC-derived MPs have shown beneficial effects in
models of acute kidney injury or CKD, as indicated by
improved histological outcomes and functional parame-
ters [36]. MPs released by MSCs can induce the same
paracrine effects as MSC therapy to regulate growth fac-
tors or cytokines and ameliorate renal inflammation and
fibrosis [37, 38]. Previously, we demonstrated that
KMSC-MPs deliver proangiogenic genes to target cells
to promote robust improvement in renal injury [39].
These beneficial paracrine effects also involve factors re-
lated to EMT, which may explain why MOCK-MPs also
significantly improved EMT and renal fibrosis. MSC-
derived MPs are also more clinically useful than MSCs
(See figure on previous page.)
Fig. 2 MPs and rhEPO attenuate TGF-β1-induced EMT in MDCK cells. A Morphological changes in TGF-β1-treated MDCK cells observed by phase
contrast microscopy. Compared to control MDCK cells (a), TGF-β1 treatment changed MDCK cell morphology from cuboidal to an elongated
spindle-like shape (b). These morphological changes were reversed by co-treatment with MOCK-MPs (c), hEPO-MPs (d), and rhEPO (e).
Fluorescence microscopy of red fluorescent CellTracker™-labeled MP incorporation into MDCK cells (m, n, r, s). Blue staining represents nuclear
counterstaining with DAPI (f–j, p–t). B RT-PCR of hEPO mRNA expression in MDCK cells co-treated with hEPO-MPs, demonstrating that MPs
mediated the horizontal transfer of hEPO mRNA into target MDCK cells. C Immunofluorescence microscopy of E-cadherin, vimentin, α-SMA, and
fibronectin in MDCK cells after co-treatment with TGF-β1 and MPs or rhEPO, indicating reduced E-cadherin immunostaining intensity in response
to TGF-β1-treatment (b) and its reversal by co-treatment with MOCK-MPs (c), hEPO-MPs (d), and rhEPO (e). TGF-β1 treatment increased vimentin
(g), α-SMA (l), and fibronectin (q) immunostaining intensity which was reversed by co-treatment with MOCK-MPs (h, m, r), hEPO-MPs (i, n, s), and
rhEPO (j, o, t). Magnification, × 400. Scale bars, 100 μm (white)
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as they circumvent concerns regarding extensive MSC
expansion or maldifferentiation in target tissues.
The therapeutic potential of MSC-derived MPs largely
depends on the nature of the original MSCs since MPs
isolated from different cells have heterogeneous mRNA
contents [40] and thus exert different therapeutic effects
under different disease conditions. It would therefore be
appealing to combine specific growth factors with regen-
erative effects against renal TECs or endothelial cells
with an MSC therapeutic platform. In this study, we
Fig. 3 Effect of MPs or rhEPO on EMT markers in MDCK cells. A–C qRT-PCR of E-cadherin, vimentin, and α-SMA mRNA in MDCK cells co-treated
with TGF-β1 and MPs or rhEPO. Compared to vehicle-treated MDCK cells, TGF-β1 treatment significantly decreased E-cadherin and increased
vimentin and α-SMA mRNA expression. MOCK-MPs, hEPO-MPs, and rhEPO reversed these changes in E-cadherin, vimentin, and α-SMA mRNA
expression. D Western blotting for E-cadherin, α-SMA, and fibronectin protein levels in MDCK cells co-treated with TGF-β1 and MPs or rhEPO.
Compared to vehicle-treated MDCK cells, TGF-β1 significantly decreased E-cadherin expression (E) and increased α-SMA and fibronectin
expression (F, G). Co-treatment with MOCK-MPs, hEPO-MPs, and rhEPO significantly ameliorated these changes induced by TGF-β1. Western
blotting data were normalized to GAPDH. Molecular weights are shown in kDa. Data are presented as mean ± SD; n = 4~5 for each experimental
group. aP < 0.05 vs. vehicle, bP < 0.05 vs. TGF-β1, cP < 0.05 vs. TGF-β1+MOCK-MPs, dP < 0.05 vs. TGF-β1+hEPO-MPs, eP < 0.05 vs. TGF-β1+rhEPO
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compared the anti-fibrotic and inhibitory effects of
MOCK-MPs and rhEPO in TGF-β-induced EMT. Previ-
ous studies have successfully used whole MOCK-MPs,
which contain all factors derived from MSCs, as a novel
therapeutic platform for acute kidney injury [22, 39]. In
this study, MOCK-MPs reduced TGF-β-induced EMT
Fig. 4 Effect of MPs and rhEPO on Smad2, Smad3, and p38 MAPK in MDCK cells. TGF-β1 significantly increased phosphorylated Smad2/Smad2
and phosphorylated Smad3/Smad3 levels (A–D) as well as phosphorylated p38/p38 (E, F) levels. hEPO-MPs and rhEPO significantly attenuated
TGF-β1-induced phosphorylated Smad2/Smad2 upregulation, whereas MOCK-MPs did not (A, B). MOCK-MPs, hEPO-MPs, and rhEPO significantly
inhibited TGF-β1-induced phosphorylated Smad3/Smad3 and phosphorylated p38/p38 upregulation with hEPO-MPs showing greatest effect (C–
F). Protein expression was calculated using NIH Image J software. Western blot data were normalized to GAPDH. Molecular weights are shown in
kDa. Data are presented as the mean ± SD; n = 4~5/for each experimental group. aP < 0.05 vs. vehicle, bP < 0.05 vs. TGF-β1, cP < 0.05 vs. TGF-
β1+MOCK-MPs, eP < 0.05 vs. TGF-β1+rhEPO
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and improved renal fibrosis in UUO kidneys; however,
the beneficial effects were significantly lesser than those
of rhEPO treatment.
EPO is the major growth factor involved in erythro-
poiesis and has been used to treat renal anemia in
patients with advanced CKD in clinical practice [41].
Studies have demonstrated that EPO has cytoprotec-
tive effects in many non-erythroid cells, including
renal TECs, which are largely attributed to anti-
apoptosis, anti-oxidant, and anti-inflammatory effects
[42]. Moreover, EPO has been shown to upregulate
miR-200 expression and attenuate hypoxia-induced
EMT in HK-2 cells [43] as well as counteract TGF-
β1-induced EMT by regulating TGF-β/Smad-2 signal-
ing and inhibit renal fibrosis in UUO kidneys [15].
Unfortunately, repetitive high-dose rhEPO treatments
were required to achieve these benefits, which would
translate to ~ 210,000 U in a 70-kg patient, approxi-
mately 10 times the dose normally administered to
patients with severe renal anemia. Such high doses
have been proven clinically unsafe and may increase
cardiovascular complications [44], thus raising con-
cerns regarding the clinical implementation of high-
dose EPO to treat renal fibrosis.
Generation of EPO-producing MSCs by genetic en-
gineering has been reported to enhance the benefits
of MSC-based treatments in cardiovascular disease by
improving their promotion of the angiogenic response
and survival potential via endocrine and autocrine
mechanisms, respectively [45]. In this study, we gen-
etically engineered KMSCs to overexpress EPO
mRNA and secrete hEPO in culture. Upon hypoxic
stimulation, hEPO-KMSCs readily secreted MPs that
were enriched with hEPO mRNA. As expected, co-
culturing MDCK cells with these isolated hEPO-MPs
resulted in the horizontal transfer of hEPO mRNA
into recipient MDCK cells and inhibited TGF-β-
induced EMT. Previous studies have demonstrated
that rhEPO treatment has potential effects on Smad
signaling pathways in EMT as well as renal fibrosis
[15]. We further investigated the effects of hEPO-MPs
on the TGF-β/non-Smad pathways during TGF-β1-
induced EMT in MDCK cells. Compared to rhEPO,
hEPO-MPs treatment displayed comparable inhibition
of Smad2 phosphorylation and greater inhibition of
Smad3 phosphorylation in TGF-β1-induced EMT
in vitro. In contrast, MOCK-MPs failed to signifi-
cantly decrease Smad2 phosphorylation. Moreover,
significant p-p38 MAPK overexpression was noted in
TGF-β-induced EMT, consistent with the known role
of the p38 MAPK pathway in renal fibrosis, acting
downstream of the TGF-β1 pathway. Unlike Smad2,
both MPs effectively inhibited p-p38 MAPK overex-
pression, with hEPO-MPs again showed a stronger ef-
fect than MOCK-MPs, supporting the beneficial
effects of hEPO-MP administration. Although the
exact significance of this finding requires further in-
vestigation, it is evident that hEPO-MPs strongly sup-
press the pSmad2, pSmad3, and p38 MAPK signaling
pathways in a manner comparable to rhEPO. Both
hEPO-MPs and MOCK-MPs inhibited renal fibrosis
in UUO kidneys, but hEPO-MPs showed greater anti-
fibrotic effect than the MOCK-MPs. Noteworthily, in
this study, repeated administration of high rhEPO
doses was needed to ameliorate renal fibrosis, rather
than a single infusion of hEPO-MPs. Previous MSC
therapies have reported the selective homing of ad-
ministered MSCs to the site of injury [22, 39], con-
sistent with our results showing the preferential
engraftment of hEPO-MPs and their EPO mRNA
contents to the inflammatory site of kidney injury,
making this delivery platform highly attractive. Gene
overexpression has been shown to enhance the thera-
peutic efficacy of MSC-derived MPs in various disease
models [29, 30]; therefore, using hEPO-MPs as a
therapeutic strategy may be more convenient as well
as physiologically relevant than systemic rhEPO ad-
ministration. To our knowledge, our findings are the
first to demonstrate that genetically modified hEPO-
MPs could be used as a novel therapeutic agent to in-
hibit renal fibrosis.
Macrophages are highly involved in the process of
renal injury and contribute toward the development
of renal fibrosis. In this study, macrophage depletion
markedly reduced myofibroblast formation and TIF in
UUO kidneys, while interstitial myofibroblast
(See figure on previous page.)
Fig. 5 Anti-fibrotic effects of MPs or rhEPO in UUO kidneys. A Microscopic analysis of Masson’s trichrome and Sirius red-stained UUO kidney
sections. Sham-operated control (a, f), obstructed kidney treated with vehicle control (b, g), and UUO kidneys treated with MOCK-MPs (c, h),
hEPO-MPs (d, i), and rhEPO (e, j). MPs and rhEPO significantly attenuated renal interstitial fibrosis as quantified using Image J and MetaMorph
software (B, C). Immunohistochemical analysis of α-SMA expression in sham-operated control (k) and UUO kidneys treated with the vehicle
control (l), MOCK-MPs (m), hEPO-MPs (n), and rhEPO (o). MPs and rhEPO significantly attenuated α-SMA expression in obstructed kidneys (D).
Immunohistochemical analysis of F4/80-positive cells in sham-operated control (p) and UUO kidneys treated with vehicle control (q), MOCK-MPs
(r), hEPO-MPs (s), and rhEPO (t). MPs and rhEPO significantly attenuated the infiltration of F4/80-positive macrophage/inflammatory cells in
obstructed kidneys. Quantitative assessment of renal F4/80-positive macrophage/inflammatory cells (E). Magnification, × 400 and × 1000 (for
inserts). Scale bars, 50 μm (black). Data are presented as the mean ± SD; n = 5 for each experimental group. aP < 0.05 vs. sham control, bP < 0.05 vs.
UUO+vehicle, cP < 0.05 vs. UUO+MOCK-MPs, dP < 0.05 vs. UUO+hEPO-MPs
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Fig. 6 Western blotting of α-SMA, collagen I, fibronectin, and TGF-β1 in UUO kidneys. Compared to the sham-operated control, the obstructed
kidneys of vehicle-treated mice showed significantly lower E-cadherin (B) and higher α-SMA (C), collagen I (D), fibronectin (E), and TGF-β1 (F)
expression. Treatment with MOCK-MPs, hEPO-MPs, and rhEPO significantly reversed these changes. Protein levels were calculated using NIH
Image J software. Western blot data were normalized to GAPDH. Molecular weights are shown in kDa. Data are presented as the mean ± SD; n =
5 for each experimental /group. aP < 0.05 vs. sham control, bP < 0.05 vs. UUO+vehicle, cP < 0.05 vs. UUO+MOCK-MPs, dP < 0.05 vs. UUO+hEPO-MPs,
eP < 0.05 vs. UUO+rhEPO
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proliferation has been shown to lead to excessive
extracellular matrix deposition and increased renal fi-
brosis [46]. Moreover, EPO administration in an ani-
mal model of CKD was found to suppress EMT and
inflammatory cell infiltration, thus reducing renal fi-
brosis [15]. These beneficial effects may be partly ex-
plained by the anti-inflammatory effects of EPO
observed in various ischemia-reperfusion injury
models [47]. Consistent with previous studies, we
showed that MPs can inhibit myofibroblast activation
and reduce F4/80-positive cell infiltration in
obstructed kidneys. In fact, hEPO-MPs were twice as
efficient at blocking the recruitment of F4/80 inflam-
matory cells in UUO kidneys, which may contribute
toward improved renal fibrosis.
The modified EPO gene-transfected MSC-based
therapy described herein is a promising therapeutic
strategy for treating CKD; however, there are several
issues that need to be resolved before it can be im-
plemented widely. Firstly, MPs derived from gene-
modified MSCs may have the potential to induce tar-
get cells to undergo malignant transformation, raising
biosafety concerns [45], even though MPs are acellu-
lar, lack proliferative capacity, and have lower tumori-
genic potential than MSCs. No studies have yet
examined the long-term effects of genetically modified
MSC-derived MPs, and further studies are required to
address this important issue. Secondly, there is uncer-
tainty regarding the optimal therapeutic dose regimen
or route of administration for MSC-derived MPs. In
this study, we investigated the benefits of hEPO-MPs
using a fixed dose regimen described in our previous
studies [24, 39]; however, the in vivo efficacy of in-
creasing MP doses or a threshold dose in experimen-
tal renal disease have not yet been reported. Dose
and injection intervals would influence the ability of
MPs to home and engraft damaged target cells,
thereby increasing their therapeutic efficacy. Future
studies should therefore determine the adequate num-
ber of MP injections and optimal intervals between
therapies. Finally, there are issues regarding the isola-
tion and quantification of MPs by different investiga-
tors. Although recent methodological guidelines have
been published to guide the proper isolation, hand-
ling, and storage of MPs [48], further studies are re-
quired to determine whether renal outcomes vary
according to protocols.
Conclusions
Our study found that hEPO-MPs contribute toward the
inhibition of TGF-β1-induced EMT in MDCK cells
in vitro and improve renal fibrosis in obstructed kidneys
in vivo in a similar manner to that of rhEPO; thus, they
may be used as a novel therapeutic agent.
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